Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Compañia de Minas Buenaventura S.A.A. (NYSE: BVN; BUE.LM) Reports First Quarter 2025 Financial and Operational Results

Compañia de Minas Buenaventura S.A.A. (NYSE: BVN; BUE.LM), a Peru-based precious metals mining company, reported its financial and operational results for the first quarter of 2025. The company recorded EBITDA of US$126.3 million from direct operations, up from US$94.5 million in the same quarter …

Team Kalkine | 01 May 2025

XPeng Inc. (NYSE: XPEV, HKEX: 9868) Reports April 2025 Deliveries and Technology Service Launch

XPeng Inc. (NYSE: XPEV, HKEX: 9868) announced vehicle delivery results for April 2025, reporting a total of 35,045 Smart EVs delivered. This figure represents a 273% increase compared to April 2024 and marks the sixth consecutive month the company has surpassed the 30,000-unit threshold. …

Team Kalkine | 01 May 2025

Zeekr Group (NYSE: ZK) Reports April 2025 Deliveries and Model Launch Updates

ZEEKR Intelligent Technology Holding Limited (NYSE: ZK) reported delivery results for April 2025, with a total of 41,316 vehicles delivered across its Zeekr and Lynk & Co brands. This marks a 1.5% increase compared to March 2025. The Zeekr brand accounted for 13,727 of …

Team Kalkine | 01 May 2025

Investor Caution Grows Ahead of Key Data as Commodities Tumble and Housing Slows

U.S. stock futures edged lower as investors awaited key economic releases, including the March PCE price index and the first estimate of Q1 GDP. Attention is also on upcoming earnings reports from Meta Platforms and Microsoft. In extended trading, Super Micro Computer (SMCI) dropped …

Team Kalkine | 30 April 2025

BriaCell Therapeutics Corp. (TSX: BCT) Presents Phase 3 Data on Biomarker-Driven Approach in Metastatic Breast Cancer

BriaCell Therapeutics Corp., a clinical-stage biotechnology company, has presented new data from its ongoing pivotal Phase 3 trial of Bria-IMT™, an investigational immunotherapy for metastatic breast cancer (MBC). The study, titled BRIA-ABC (NCT06072612), explores how specific biomarkers might predict patient response to the Bria-IMT …

Team Kalkine | 30 April 2025

Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) Signs Landmark B2B Pre-Order Deal for 1,000 FX Super One MPVs

Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) has signed its first binding B2B pre-order agreement for its FX Super One MPV, marking a significant commercial development. The agreement, involving New York City dealership 129 Auto Sales Corp. (operating as JC Auto), includes a $100,000 …

Team Kalkine | 30 April 2025

Basel Medical Group Ltd (Nasdaq: BMGL) Finalizes Acquisition of Bethesda Medical to Expand Southeast Asia Presence

Basel Medical Group Ltd (Nasdaq: BMGL) has completed the acquisition of Bethesda Medical Pte. Ltd., a Singapore-based healthcare provider with three decades of experience in diagnostic imaging and outpatient medical services. The move strengthens Basel Medical’s footprint in Singapore and initiates its broader strategy …

Team Kalkine | 30 April 2025

nCino, Inc. (NASDAQ: NCNO) Enters Luxembourg Market Through Partnership with Banque Raiffeisen

nCino, Inc. (NASDAQ: NCNO) has announced its entry into Luxembourg through a new partnership with Banque Raiffeisen, the country’s only cooperative bank. The agreement will see Banque Raiffeisen implement the nCino platform to digitize its loan and credit chain management operations.

Team Kalkine | 30 April 2025

Markets Await Tech Earnings and Economic Data Amid Trade Uncertainty

U.S. stock futures rose on Tuesday as investors awaited earnings from major tech firms like Meta, Microsoft, Apple, and Amazon. While most S&P 500 companies have beaten earnings expectations, many are lowering future guidance due to tariff concerns. Treasury Secretary Scott Bessent said it's …

Team Kalkine | 29 April 2025

European Commission Grants Standard Marketing Authorization for FILSPARI (NASDAQ: TVTX) in IgA Nephropathy Treatment

The European Commission has approved the conversion of the conditional marketing approval (CMA) for FILSPARI into a standard marketing authorization (MA) for the treatment of primary IgA nephropathy (IgAN) in adults with a urine protein excretion of ≥1.0 g/day. This authorization applies across all …

Team Kalkine | 29 April 2025
Support

Hi! How can we help you today?

Loading…